Do analysts rate XRTX or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to XRTX or BFRI?

In the previous week, Biofrontera had 1 more articles in the media than XORTX Therapeutics. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for XORTX Therapeutics. Biofrontera's average media sentiment score of 1.00 beat XORTX Therapeutics' score of -0.67 indicating that Biofrontera is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XORTX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XRTX or SCNX?

Scienture has a consensus price target of $1.50, suggesting a potential upside of 294.63%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than XORTX Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scienture 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XRTX or SCNX more profitable?

Scienture's return on equity of -56.28% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Scienture N/A -56.28% -44.76%

Do analysts rate XRTX or CABR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Caring Brands 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, XRTX or CABR?

Caring Brands is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A Caring Brands N/A N/A -$6.28M -$0.64 N/A

Is XRTX or CABR more profitable?

Caring Brands' return on equity of 0.00% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Caring Brands N/A N/A N/A

Do analysts recommend XRTX or GRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, XRTX or GRTX?

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A Galera Therapeutics N/A N/A -$59.08M $0.64 0.14

Is XRTX or GRTX more profitable?

Galera Therapeutics' return on equity of 0.00% beat XORTX Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Galera Therapeutics N/A N/A -99.34%

Does the media prefer XRTX or GRTX?

In the previous week, XORTX Therapeutics and XORTX Therapeutics both had 1 articles in the media. Galera Therapeutics' average media sentiment score of 0.00 beat XORTX Therapeutics' score of -0.67 indicating that Galera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XORTX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Galera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XRTX or COCP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XORTX Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, XRTX or COCP?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XORTX Therapeutics N/A N/A -$2.66M -$2.63 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.73 N/A

Is XRTX or COCP more profitable?

XORTX Therapeutics' return on equity of -150.01% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets XORTX Therapeutics N/A -150.01% -106.53% Cocrystal Pharma N/A -150.61% -97.86%

Does the media favor XRTX or COCP?

In the previous week, Cocrystal Pharma had 2 more articles in the media than XORTX Therapeutics. MarketBeat recorded 3 mentions for Cocrystal Pharma and 1 mentions for XORTX Therapeutics. Cocrystal Pharma's average media sentiment score of 0.33 beat XORTX Therapeutics' score of -0.67 indicating that Cocrystal Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XORTX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

XORTX Therapeutics (XRTX) Competitors

$2.13 0.00 (0.00%)

Closing price 08/7/2026 03:57 PM Eastern

Extended Trading

$2.13 0.00 (0.00%)

As of 08/7/2026 07:34 PM Eastern

Compare

XRTX vs. BFRI, SCNX, CABR, GRTX, and COCP

Should you buy XORTX Therapeutics stock or one of its competitors? MarketBeat compares XORTX Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XORTX Therapeutics include Biofrontera (BFRI), Scienture (SCNX), Caring Brands (CABR), Galera Therapeutics (GRTX), and Cocrystal Pharma (COCP). These companies are all part of the "pharmaceuticals" industry.

How does XORTX Therapeutics compare to Biofrontera?

XORTX Therapeutics (NASDAQ:XRTX) and Biofrontera (NASDAQ:BFRI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by insiders. Comparatively, 8.1% of Biofrontera shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

XORTX Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. XORTX Therapeutics' return on equity of -150.01% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Biofrontera	-25.66%	-515.34%	-53.91%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Biofrontera had 1 more articles in the media than XORTX Therapeutics. MarketBeat recorded 2 mentions for Biofrontera and 1 mentions for XORTX Therapeutics. Biofrontera's average media sentiment score of 1.00 beat XORTX Therapeutics' score of -0.67 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XORTX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

XORTX Therapeutics has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Biofrontera has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

XORTX Therapeutics has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Biofrontera	$43.20M	0.38	-$10.54M	-$0.97	N/A

Summary

Biofrontera beats XORTX Therapeutics on 10 of the 14 factors compared between the two stocks.

How does XORTX Therapeutics compare to Scienture?

XORTX Therapeutics (NASDAQ:XRTX) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Scienture's return on equity of -56.28% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Scienture	N/A	-56.28%	-44.76%

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by insiders. Comparatively, 21.4% of Scienture shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, XORTX Therapeutics had 1 more articles in the media than Scienture. MarketBeat recorded 1 mentions for XORTX Therapeutics and 0 mentions for Scienture. Scienture's average media sentiment score of 0.00 beat XORTX Therapeutics' score of -0.67 indicating that Scienture is being referred to more favorably in the news media.

Company	Overall Sentiment
XORTX Therapeutics	Negative
Scienture	Neutral

Scienture has a consensus price target of $1.50, suggesting a potential upside of 294.63%. Given Scienture's stronger consensus rating and higher probable upside, analysts plainly believe Scienture is more favorable than XORTX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scienture	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

XORTX Therapeutics has higher earnings, but lower revenue than Scienture. XORTX Therapeutics is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Scienture	$430K	35.92	-$41.51M	-$2.51	N/A

XORTX Therapeutics has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Scienture has a beta of 3.26, indicating that its stock price is 226% more volatile than the broader market.

Summary

Scienture beats XORTX Therapeutics on 12 of the 14 factors compared between the two stocks.

How does XORTX Therapeutics compare to Caring Brands?

XORTX Therapeutics (NASDAQ:XRTX) and Caring Brands (NASDAQ:CABR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

0.2% of XORTX Therapeutics shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 14.6% of Caring Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Caring Brands' return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Caring Brands	N/A	N/A	N/A

In the previous week, XORTX Therapeutics had 1 more articles in the media than Caring Brands. MarketBeat recorded 1 mentions for XORTX Therapeutics and 0 mentions for Caring Brands. Caring Brands' average media sentiment score of 0.00 beat XORTX Therapeutics' score of -0.67 indicating that Caring Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
XORTX Therapeutics	Negative
Caring Brands	Neutral

Caring Brands is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Caring Brands	N/A	N/A	-$6.28M	-$0.64	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Caring Brands	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Caring Brands beats XORTX Therapeutics on 5 of the 9 factors compared between the two stocks.

How does XORTX Therapeutics compare to Galera Therapeutics?

XORTX Therapeutics (NASDAQ:XRTX) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

XORTX Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Galera Therapeutics' return on equity of 0.00% beat XORTX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Galera Therapeutics	N/A	N/A	-99.34%

In the previous week, XORTX Therapeutics and XORTX Therapeutics both had 1 articles in the media. Galera Therapeutics' average media sentiment score of 0.00 beat XORTX Therapeutics' score of -0.67 indicating that Galera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XORTX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Galera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by insiders. Comparatively, 12.9% of Galera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

XORTX Therapeutics has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Galera Therapeutics has a beta of 2.6, meaning that its share price is 160% more volatile than the broader market.

Summary

Galera Therapeutics beats XORTX Therapeutics on 8 of the 10 factors compared between the two stocks.

How does XORTX Therapeutics compare to Cocrystal Pharma?

XORTX Therapeutics (NASDAQ:XRTX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Cocrystal Pharma is trading at a lower price-to-earnings ratio than XORTX Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XORTX Therapeutics	N/A	N/A	-$2.66M	-$2.63	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.73	N/A

XORTX Therapeutics' return on equity of -150.01% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XORTX Therapeutics	N/A	-150.01%	-106.53%
Cocrystal Pharma	N/A	-150.61%	-97.86%

In the previous week, Cocrystal Pharma had 2 more articles in the media than XORTX Therapeutics. MarketBeat recorded 3 mentions for Cocrystal Pharma and 1 mentions for XORTX Therapeutics. Cocrystal Pharma's average media sentiment score of 0.33 beat XORTX Therapeutics' score of -0.67 indicating that Cocrystal Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XORTX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Cocrystal Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.2% of XORTX Therapeutics shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 6.9% of XORTX Therapeutics shares are held by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

XORTX Therapeutics has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XORTX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cocrystal Pharma beats XORTX Therapeutics on 7 of the 10 factors compared between the two stocks.

Get XORTX Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XRTX vs. The Competition

Export

Metric	XORTX Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.88M	$11.85B	$7.00B	$12.99B
Dividend Yield	N/A	2.70%	2.58%	10.20%
P/E Ratio	-0.81	790.97	270.59	25.05
Price / Sales	N/A	739.02	599.41	84.35
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	1.42	10.28	11.21	6.43
Net Income	-$2.66M	$2.78B	$3.45B	$348.10M
7 Day Performance	N/A	2.74%	3.41%	2.68%
1 Month Performance	1.43%	-0.66%	-0.71%	-0.83%
1 Year Performance	-46.42%	192.51%	77.31%	23.97%

XORTX Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XRTX XORTX Therapeutics	0.6474 of 5 stars	$2.13 flat	N/A	-46.4%	$3.88M	N/A	N/A	N/A	Upcoming Earnings
BFRI Biofrontera	1.406 of 5 stars	$1.25 +0.8%	N/A	+34.2%	$15.88M	$41.71M	N/A	70	Positive News Upcoming Earnings
SCNX Scienture	1.7145 of 5 stars	$0.37 -4.2%	$1.50 +302.5%	-81.9%	$15.81M	$430K	N/A	N/A	Upcoming Earnings Gap Down
CABR Caring Brands	0.5122 of 5 stars	$1.61 +3.2%	N/A	N/A	$14.18M	N/A	N/A	4	Gap Up High Trading Volume
GRTX Galera Therapeutics	N/A	$0.09 flat	N/A	+282.6%	$14.12M	N/A	N/A	30	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XRTX) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XORTX Therapeutics (XRTX) Competitors

XRTX vs. BFRI, SCNX, CABR, GRTX, and COCP

How does XORTX Therapeutics compare to Biofrontera?

Summary

How does XORTX Therapeutics compare to Scienture?

Summary

How does XORTX Therapeutics compare to Caring Brands?

Summary

How does XORTX Therapeutics compare to Galera Therapeutics?

Summary

How does XORTX Therapeutics compare to Cocrystal Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XORTX Therapeutics (XRTX) Competitors

XRTX vs. BFRI, SCNX, CABR, GRTX, and COCP

How does XORTX Therapeutics compare to Biofrontera?

Do institutionals & insiders have more ownership in XRTX or BFRI?

Is XRTX or BFRI more profitable?

Do analysts rate XRTX or BFRI?

Does the media refer more to XRTX or BFRI?

Which has more risk and volatility, XRTX or BFRI?

Which has better earnings & valuation, XRTX or BFRI?

Summary

How does XORTX Therapeutics compare to Scienture?

Is XRTX or SCNX more profitable?

Do institutionals & insiders hold more shares of XRTX or SCNX?

Does the media favor XRTX or SCNX?

Do analysts recommend XRTX or SCNX?

Which has higher earnings & valuation, XRTX or SCNX?

Which has more risk and volatility, XRTX or SCNX?

Summary

How does XORTX Therapeutics compare to Caring Brands?

Do institutionals & insiders have more ownership in XRTX or CABR?

Is XRTX or CABR more profitable?

Does the media refer more to XRTX or CABR?

Which has stronger valuation and earnings, XRTX or CABR?

Do analysts rate XRTX or CABR?

Summary

How does XORTX Therapeutics compare to Galera Therapeutics?

Which has stronger valuation & earnings, XRTX or GRTX?

Do analysts recommend XRTX or GRTX?

Is XRTX or GRTX more profitable?

Does the media prefer XRTX or GRTX?

Do institutionals and insiders believe in XRTX or GRTX?

Which has more volatility and risk, XRTX or GRTX?

Summary

How does XORTX Therapeutics compare to Cocrystal Pharma?

Which has higher valuation & earnings, XRTX or COCP?

Is XRTX or COCP more profitable?

Does the media favor XRTX or COCP?

Do insiders and institutionals have more ownership in XRTX or COCP?

Which has more risk and volatility, XRTX or COCP?

Do analysts rate XRTX or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XRTX vs. The Competition

XORTX Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools